Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(4):486–493. doi: 10.1038/bjc.1997.414

The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer.

K Nooter 1, G Brutel de la Riviere 1, M P Look 1, K E van Wingerden 1, S C Henzen-Logmans 1, R J Scheper 1, M J Flens 1, J G Klijn 1, G Stoter 1, J A Foekens 1
PMCID: PMC2227995  PMID: 9275026

Abstract

In the present study, we determined the frequency and intensity of MRP protein expression by monoclonal antibody immunohistochemistry in a series of 259 resected invasive primary breast carcinomas, and we evaluated MRP immunoreactivity in relation to patient and tumour characteristics, relapse-free (RFS) and overall survival (OS). The immunostaining was graded on a semiquantitative scale that ranged from (-) to ( ). Overall, 34% of the tumours were positive for anti-MRP antibody: 19% showed weak cytoplasmic staining (+), 14% had clear cytoplasmic staining (++) and only 1% of the tumours had a strong cytoplasmic as well as membranous staining ( ). MRP expression was not related to patient's age, menopausal status, tumour size, differentiation grade, oestrogen and progesterone receptor level or lymph node involvement. In an exploratory univariate analysis of all patients, only primary tumour size and number of lymph nodes involved were significantly associated with shortened RFS (P < 0.001 and P < 0.001 respectively) and OS (P = 0.02 and P < 0.001 respectively). In Cox univariate analysis for RFS in subgroups of patients stratified by menopausal status, tumour size, nodal status, adjuvant systemic therapy and oestrogen and progesterone receptor status, MRP expression was associated with increased risk for failure in patients with small tumours (T1), in node-negative patients and in node-positive patients who received adjuvant systemic chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF); the relative hazard rate (RHR) for relapse was increased in the presence of MRP, with RHR values with 95% confidence limits (CL) of 2.8 (1.2-6.9), 2.1 (1.0-4.2) and 2.8 (0.8-9.9) respectively. In analysis for OS, expression of MRP was also associated with increased risk for failure in patients with small tumours (T1) [RHR (95% CL) 2.3 (0.9-6.0)] and in node-positive patients who received adjuvant systemic chemotherapy with CMF [RHR (95% CL) 3.7 (0.8-17.1)] but not in node-negative patients [RHR (95% CL) 1.1 (0.4-2.6)]. In conclusion, our results show that MRP is frequently overexpressed in primary breast cancer and suggest that MRP expression might be of prognostic significance in the subgroups of patients with the more favourable prognosis, i.e. patients with small tumours and node-negative patients, as well as in the setting of adjuvant systemic chemotherapy. In primary breast cancer, MRP might be related to altered cell biological behaviour, including a more aggressive phenotype, and resistance to adjuvant systemic chemotherapy.

Full text

PDF
486

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bordow S. B., Haber M., Madafiglio J., Cheung B., Marshall G. M., Norris M. D. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res. 1994 Oct 1;54(19):5036–5040. [PubMed] [Google Scholar]
  2. Breuninger L. M., Paul S., Gaughan K., Miki T., Chan A., Aaronson S. A., Kruh G. D. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995 Nov 15;55(22):5342–5347. [PubMed] [Google Scholar]
  3. Burger H., Nooter K., Sonneveld P., Van Wingerden K. E., Zaman G. J., Stoter G. High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. Br J Haematol. 1994 Oct;88(2):348–356. doi: 10.1111/j.1365-2141.1994.tb05030.x. [DOI] [PubMed] [Google Scholar]
  4. Childs S., Ling V. The MDR superfamily of genes and its biological implications. Important Adv Oncol. 1994:21–36. [PubMed] [Google Scholar]
  5. Cole S. P., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M., Deeley R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992 Dec 4;258(5088):1650–1654. doi: 10.1126/science.1360704. [DOI] [PubMed] [Google Scholar]
  6. Cole S. P., Sparks K. E., Fraser K., Loe D. W., Grant C. E., Wilson G. M., Deeley R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994 Nov 15;54(22):5902–5910. [PubMed] [Google Scholar]
  7. Doyle L. A. Mechanisms of drug resistance in human lung cancer cells. Semin Oncol. 1993 Aug;20(4):326–337. [PubMed] [Google Scholar]
  8. Endo K., Maehara Y., Ichiyoshi Y., Kusumoto T., Sakaguchi Y., Ohno S., Sugimachi K. Multidrug resistance-associated protein expression in clinical gastric carcinoma. Cancer. 1996 Apr 15;77(8 Suppl):1681–1687. doi: 10.1002/(SICI)1097-0142(19960415)77:8<1681::AID-CNCR39>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  9. Filipits M., Suchomel R. W., Dekan G., Haider K., Valdimarsson G., Depisch D., Pirker R. MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res. 1996 Jul;2(7):1231–1237. [PubMed] [Google Scholar]
  10. Flens M. J., Izquierdo M. A., Scheffer G. L., Fritz J. M., Meijer C. J., Scheper R. J., Zaman G. J. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 1994 Sep 1;54(17):4557–4563. [PubMed] [Google Scholar]
  11. Flens M. J., Zaman G. J., van der Valk P., Izquierdo M. A., Schroeijers A. B., Scheffer G. L., van der Groep P., de Haas M., Meijer C. J., Scheper R. J. Tissue distribution of the multidrug resistance protein. Am J Pathol. 1996 Apr;148(4):1237–1247. [PMC free article] [PubMed] [Google Scholar]
  12. Foekens J. A., Portengen H., van Putten W. L., Peters H. A., Krijnen H. L., Alexieva-Figusch J., Klijn J. G. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res. 1989 Nov 1;49(21):5823–5828. [PubMed] [Google Scholar]
  13. Grant C. E., Valdimarsson G., Hipfner D. R., Almquist K. C., Cole S. P., Deeley R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994 Jan 15;54(2):357–361. [PubMed] [Google Scholar]
  14. Harris J. R., Lippman M. E., Veronesi U., Willett W. Breast cancer (3). N Engl J Med. 1992 Aug 13;327(7):473–480. doi: 10.1056/NEJM199208133270706. [DOI] [PubMed] [Google Scholar]
  15. Hipfner D. R., Gauldie S. D., Deeley R. G., Cole S. P. Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res. 1994 Nov 15;54(22):5788–5792. [PubMed] [Google Scholar]
  16. Kavallaris M., Leary J. A., Barrett J. A., Friedlander M. L. MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett. 1996 Apr 19;102(1-2):7–16. doi: 10.1016/0304-3835(96)04143-2. [DOI] [PubMed] [Google Scholar]
  17. Klijn J. G., Berns E. M., Bontenbal M., Foekens J. Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev. 1993 Apr;19 (Suppl B):45–63. doi: 10.1016/0305-7372(93)90007-e. [DOI] [PubMed] [Google Scholar]
  18. Krishnamachary N., Center M. S. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 1993 Aug 15;53(16):3658–3661. [PubMed] [Google Scholar]
  19. Kruh G. D., Chan A., Myers K., Gaughan K., Miki T., Aaronson S. A. Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res. 1994 Apr 1;54(7):1649–1652. [PubMed] [Google Scholar]
  20. Kuss B. J., Deeley R. G., Cole S. P., Willman C. L., Kopecky K. J., Wolman S. R., Eyre H. J., Lane S. A., Nancarrow J. K., Whitmore S. A. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet. 1994 Jun 18;343(8912):1531–1534. doi: 10.1016/s0140-6736(94)92938-6. [DOI] [PubMed] [Google Scholar]
  21. Kuttesch J. F., Parham D. M., Luo X., Meyer W. H., Bowman L., Shapiro D. N., Pappo A. S., Crist W. M., Beck W. T., Houghton P. J. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol. 1996 Mar;14(3):886–900. doi: 10.1200/JCO.1996.14.3.886. [DOI] [PubMed] [Google Scholar]
  22. Lai S. L., Goldstein L. J., Gottesman M. M., Pastan I., Tsai C. M., Johnson B. E., Mulshine J. L., Ihde D. C., Kayser K., Gazdar A. F. MDR1 gene expression in lung cancer. J Natl Cancer Inst. 1989 Aug 2;81(15):1144–1150. doi: 10.1093/jnci/81.15.1144. [DOI] [PubMed] [Google Scholar]
  23. Linn S. C., Giaccone G., van Diest P. J., Blokhuis W. M., van der Valk P., van Kalken C. K., Kuiper C. M., Pinedo H. M., Baak J. P. Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol. 1995 Sep;6(7):679–685. doi: 10.1093/oxfordjournals.annonc.a059284. [DOI] [PubMed] [Google Scholar]
  24. McGuire W. L., Clark G. M. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med. 1992 Jun 25;326(26):1756–1761. doi: 10.1056/NEJM199206253262607. [DOI] [PubMed] [Google Scholar]
  25. Merkel D. E., Fuqua S. A., Tandon A. K., Hill S. M., Buzdar A. U., McGuire W. L. Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol. 1989 Aug;7(8):1129–1136. doi: 10.1200/JCO.1989.7.8.1129. [DOI] [PubMed] [Google Scholar]
  26. Nooter K., Bosman F. T., Burger H., van Wingerden K. E., Flens M. J., Scheper R. J., Oostrum R. G., Boersma A. W., van der Gaast A., Stoter G. Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. Ann Oncol. 1996 Jan;7(1):75–81. doi: 10.1093/oxfordjournals.annonc.a010484. [DOI] [PubMed] [Google Scholar]
  27. Nooter K., Burger H., Stoter G. Multidrug resistance-associated protein (MRP) in haematological malignancies. Leuk Lymphoma. 1996 Feb;20(5-6):381–387. doi: 10.3109/10428199609052419. [DOI] [PubMed] [Google Scholar]
  28. Nooter K., Sonneveld P. Clinical relevance of P-glycoprotein expression in haematological malignancies. Leuk Res. 1994 Apr;18(4):233–243. doi: 10.1016/0145-2126(94)90025-6. [DOI] [PubMed] [Google Scholar]
  29. Nooter K., Westerman A. M., Flens M. J., Zaman G. J., Scheper R. J., van Wingerden K. E., Burger H., Oostrum R., Boersma T., Sonneveld P. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res. 1995 Nov;1(11):1301–1310. [PubMed] [Google Scholar]
  30. Ota E., Abe Y., Oshika Y., Ozeki Y., Iwasaki M., Inoue H., Yamazaki H., Ueyama Y., Takagi K., Ogata T. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer. 1995 Sep;72(3):550–554. doi: 10.1038/bjc.1995.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Paul S., Breuninger L. M., Tew K. D., Shen H., Kruh G. D. ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):6929–6934. doi: 10.1073/pnas.93.14.6929. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  32. Schneider E., Cowan K. H., Bader H., Toomey S., Schwartz G. N., Karp J. E., Burke P. J., Kaufmann S. H. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood. 1995 Jan 1;85(1):186–193. [PubMed] [Google Scholar]
  33. Thomas G. A., Barrand M. A., Stewart S., Rabbitts P. H., Williams E. D., Twentyman P. R. Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation. Eur J Cancer. 1994;30A(11):1705–1709. doi: 10.1016/0959-8049(94)00290-l. [DOI] [PubMed] [Google Scholar]
  34. Tobe S. W., Noble-Topham S. E., Andrulis I. L., Hartwick R. W., Skorecki K. L., Warner E. Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage. Clin Cancer Res. 1995 Dec;1(12):1611–1615. [PubMed] [Google Scholar]
  35. Weinstein R. S., Jakate S. M., Dominguez J. M., Lebovitz M. D., Koukoulis G. K., Kuszak J. R., Klusens L. F., Grogan T. M., Saclarides T. J., Roninson I. B. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res. 1991 May 15;51(10):2720–2726. [PubMed] [Google Scholar]
  36. Zaman G. J., Flens M. J., van Leusden M. R., de Haas M., Mülder H. S., Lankelma J., Pinedo H. M., Scheper R. J., Baas F., Broxterman H. J. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8822–8826. doi: 10.1073/pnas.91.19.8822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Zaman G. J., Versantvoort C. H., Smit J. J., Eijdems E. W., de Haas M., Smith A. J., Broxterman H. J., Mulder N. H., de Vries E. G., Baas F. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 1993 Apr 15;53(8):1747–1750. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES